danazol
E850019
Danazol is a synthetic androgen used primarily to treat endometriosis, fibrocystic breast disease, and hereditary angioedema.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Danazol | 0 |
Statements (58)
| Predicate | Object |
|---|---|
| instanceOf |
medication
ⓘ
small molecule ⓘ steroidal drug ⓘ synthetic androgen ⓘ |
| affectsSystem |
endocrine system
ⓘ
hepatic system ⓘ reproductive system ⓘ |
| contraindicatedIn |
breastfeeding
ⓘ
porphyria ⓘ pregnancy ⓘ severe cardiac disease ⓘ severe hepatic impairment ⓘ severe renal impairment ⓘ |
| hasAdverseEffect |
acne
ⓘ
decreased breast size ⓘ elevated liver enzymes ⓘ headache ⓘ hirsutism ⓘ hot flashes ⓘ hyperlipidemia ⓘ menstrual irregularities ⓘ mood changes ⓘ oily skin ⓘ thromboembolic events ⓘ voice deepening ⓘ weight gain ⓘ |
| hasATCCode | G03XA01 ⓘ |
| hasBioavailability | variable oral bioavailability ⓘ |
| hasCASNumber | 17230-88-5 ⓘ |
| hasChemicalFormula | C22H27NO2 ⓘ |
| hasDrugBankID | DB01260 ⓘ |
| hasHalfLife | approximately 24 hours ⓘ |
| hasIUPACName | (1S,10S,11S,14S,15S)-14-ethyl-14-hydroxy-3-oxo-2,3,4,7,8,9,10,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthrene-17-carbonitrile ⓘ |
| hasMechanismOfAction |
binding to sex hormone-binding globulin
ⓘ
increase of C1 esterase inhibitor levels ⓘ inhibition of mid-cycle surge of luteinizing hormone ⓘ reduction of estrogen production ⓘ suppression of pituitary gonadotropin secretion ⓘ weak androgen receptor agonism ⓘ |
| hasMolarMass | 337.46 g/mol ⓘ |
| hasPharmacologicalClass |
androgen
ⓘ
antigonadotropin ⓘ gonadotropin-release inhibitor ⓘ |
| hasPregnancyCategory | X (US) ⓘ |
| hasPubChemCID | 2956 ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasUNII | 9AYD343T1E ⓘ |
| isAdministeredAs | oral capsule ⓘ |
| isDerivativeOf | ethisterone NERFINISHED ⓘ |
| isEliminatedVia |
feces
ⓘ
urine ⓘ |
| isMetabolizedIn | liver ⓘ |
| isTeratogenic | true ⓘ |
| usedFor |
endometriosis
ⓘ
fibrocystic breast disease ⓘ hereditary angioedema ⓘ menorrhagia associated with uterine fibroids ⓘ prevention of angioedema attacks in hereditary angioedema ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.